Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs

BMJ Quality and Safety

Volumn 22, Issue 9, 2013, Pages 727-734

  Kesselheim, Aaron S ^a   Franklin, Jessica M ^a   Avorn, Jerry ^a   Duke, Jon D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATORVASTATIN; BEVACIZUMAB; CLOPIDOGREL; DULOXETINE; ENOXAPARIN; ESCITALOPRAM; ESOMEPRAZOLE; ETANERCEPT; FLUTICASONE; INFLIXIMAB; MONTELUKAST; OLANZAPINE; OXYCODONE; PIOGLITAZONE; PRESCRIPTION DRUG; QUETIAPINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROSUVASTATIN; SALMETEROL; VENLAFAXINE;

ABDOMINAL DISTENSION; ANOREXIA; ARTICLE; AUSTRALIA; BILIARY TRACT PAIN; BRUXISM; CANADA; CHEILITIS; CHOLECYSTITIS; CHOLELITHIASIS; COLITIS; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG FATALITY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DUODENITIS; DYSPHAGIA; ERUCTATION; ESOPHAGITIS; ESOPHAGUS SPASM; FATTY LIVER; FOOD AND DRUG ADMINISTRATION; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL REFLUX; GINGIVA BLEEDING; GINGIVITIS; GLOSSITIS; HEART FAILURE; HEMATEMESIS; HEMORRHOID; HEPATITIS; HUMAN; ILEITIS; INCREASED APPETITE; INTERNATIONAL COOPERATION; INTESTINE OBSTRUCTION; JAUNDICE; LANGUAGE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER INJURY; LIVER NECROSIS; LUNG HEMORRHAGE; MELENA; MOUTH ULCER; NATURAL LANGUAGE PROCESSING; PANCREATITIS; PAROTITIS; PATIENT SAFETY; PERIODONTITIS; PRESCRIPTION; PROCTITIS; RECTUM DISEASE; RECTUM HEMORRHAGE; SALIVATION; SIDE EFFECT; STOMATITIS; THRUSH; TONGUE EDEMA; UNITED KINGDOM; UNITED STATES; VOMITING;

ADVERSE EVENTS, EPIDEMIOLOGY AND DETECTION; COMMUNICATION; HEALTH POLICY; INFORMATION TECHNOLOGY; MEDICATION SAFETY;

CONSUMER PRODUCT SAFETY; DEVELOPED COUNTRIES; DRUG LABELING; HUMANS; NATURAL LANGUAGE PROCESSING; POISSON DISTRIBUTION; PRESCRIPTION DRUGS;

EID: 84882350639     PISSN: 20445415     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmjqs-2012-001704     Document Type: Article

References (38)

1. Department of Health and Human Services. Requirements on content and format of labeling for human prescription drug and biological products. 21 C.F.R. 201.56. Silver Spring, MD: US Food and Drug Administration, 2011.
2. Lal R, Kremzner M. Introduction to the new prescription drug labeling by the Food and Drug Administration. Am J Health Syst Pharm 2007;64:2488-94.
3. Busch SH, Frank RG, Leslie DL, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv 2010;61:11-16.
4. Tamblyn R, Abrahamowicz M, Dauphinee D, et al. Influence of physicians' management and communication ability on patients' persistence with antihypertensive medication. Arch Intern Med 2010;170:1064-72.
5. Weymiller AJ, Montori VM, Jones LA, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med 2007;167:1076-82.
6. Edwards A, Elwyn G. Understanding risk and lessons for clinical risk communication about treatment preferences. Qual Health Care 2001;10(Suppl 1):i9-13.
7. Calabrese AT, Cholka K, Lenhart SE, et al. Pharmacist involvement in a multidisciplinary inpatient medication education program. Am J Health Syst Pharm 2003;60:1012-18.
8. Thürmann PA. Safety and risk communication to patients. Expert Opin Drug Saf 2006;5:747-50.
9. Avorn J, Shrank W. Highlights and a hidden hazard-the FDA's new labeling regulations. N Engl J Med 2006;354: 2409-11.
10. Imbroscio M, Bell G. Adequate drug warnings in the face of uncertain causality: the learned intermediary doctrine and the need for clarity. West Virginia Law Rev 2005;107:847-65.
11. Schwartz LM, Woloshin S. Lost in transmission-FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20.
12. Shulman LP, Bateman LH, Creinin MD, et al. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling. Contraception 2006;73:440-2.
13. Soumerai SB, Avorn J, Gortmaker S, et al. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. Am J Public Health 1987;77:1518-23.
14. Duke J, Friedlin J, Ryan P. A quantitative analysis of adverse events and 'overwarning' in drug labeling. Arch Intern Med 2011;171:944-6.
15. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A Knopf, 2004.
16. Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med 2012;367:1679-81.
17. Burnier M. The safety of rofecoxib. Expert Opin Drug Saf 2005;4:491-9.
18. Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf 2013;22:294-301.
19. Daily Med: about Daily Med. http://dailymed.nlm.nih.gov/dailymed/about. cfm (accessed 16 Apr 2013).
20. Government of Canada HC. Drug Product Database Online Query. http://webprod5.hc-sc.gc.ca/dpd-bdpp (accessed 17 Apr 2013).
21. What's new-Electronic Medicines Compendium (eMC). http://www.medicines. org.uk/emc/ (accessed 16 Apr 2013).
22. Australian Government Department of Health and Ageing. Information about prescription medicines in Australia. https://www.ebs.tga.gov.au (accessed 17 Apr 2013).
23. Bartholomew M. Top 200 prescription drugs of 2009. http://www. pharmacytimes.com/publications/issue/2010/May2010/RxFocusTopDrugs-0510 (accessed 16 Apr 2013).
24. Center for Drug Evaluation and Research. Drugs@FDA data files. http://www.fda.gov/Drugs/InformationOnDrugs/ucm079750.htm (accessed 16 Apr 2013).
25. Duke JD, Friedlin J. ADESSA: a real-time decision support service for delivery of semantically coded adverse drug event data. AMIA Annu Symp Proc 2010;2010:177-81.
26. First Data Bank. FDB Med Knowledge. http://www.fdbhealth.com/fdb- medknowledge-clinical-modules/ (accessed 16 Apr 2013).
27. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
28. Raynor DK, Svarstad B, Knapp P, et al. Consumer medication information in the United States, Europe, and Australia: a comparative evaluation. J Am Pharm Assoc 2007; 47:717-24.
29. Buckley NA, Rossi S. Bringing greater transparency to 'black box' warnings. Clin Toxicol 2011;49:448-51.
30. HealthCanada. Transparency-release of product monographs directly to requesters. 29 May 2006. http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/ pdf/prodpharma/pm-notice-mp-avis-trans-eng.pdf (accessed 16 Apr 2013).
31. Chen DT, Wynia MK, Moloney RM, et al. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009;18:1094-100.
32. Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health 2007;97:750-4.
33. Berenson A. For Merck, the Vioxx paper trail won't go away. NY Times 21 August 2005; A1.
34. Eguale T, Buckeridge DL, Winslade NE, et al. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012;172:781-8.
35. Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 2006;166:338-44.
36. Busch SH, Barry CL. Pediatric antidepressant use after the black-box warning. Health Aff 2009;28:724-33.
37. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med 2001;47:199-203.
38. Herxheimer A. Communicating with patients about harms and risks. PLoS Med 2005;2:e42.